Related references
Note: Only part of the references are listed.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
Ulf Kallweit et al.
CLINICAL NEUROPHARMACOLOGY (2012)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2011)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
J. Theodore Phillips et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
F. Sangalli et al.
NEUROLOGICAL SCIENCES (2011)
Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland
Norman Putzki et al.
EUROPEAN NEUROLOGY (2010)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Share Paper
